Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines hormonal therapies for acne in females, noting their effectiveness and encouraging further study and use to reduce antibiotic reliance, but it reports no new results.

This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.

This review discusses the roles of androgens and androgen receptor in skin diseases like acne and hirsutism, and highlights the promise of antiandrogen drugs, reporting no new clinical findings.

In this study, researchers developed a probiotic-based microneedle system combining Weissella cibaria and clascoterone to target androgenetic alopecia, which in a mouse model improved hair density, vascular regeneration, and reduced inflammation, suggesting a promising treatment approach.

Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.

This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.

Combining microneedling with drugs and stem cells shows promise for improving hair growth in androgenetic alopecia.

This review updates dermatologists on both FDA-approved and off-label hormonal therapies, including combined oral contraceptives, clascoterone, and spironolactone, used for acne treatment, providing insights into emerging approaches for managing the condition.

This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.

This review discusses the multifactorial pathogenesis of acne and current treatment strategies including the use of isotretinoin and spironolactone, but reports no new clinical results.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This study reported that clascoterone cream reduced inflammatory and noninflammatory acne lesions in a trial with 1440 white males and non-pregnant females, showing it was well tolerated in these participants.

This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.

Azathioprine may help with severe hair loss, a new topical treatment could counteract hair thinning, and trichoscopy can diagnose hair-pulling disorder effectively.

Cortexolone 17a-propionate may be an effective new treatment for hair loss.

This study provided 18 evidence-based recommendations for managing acne vulgaris, strongly endorsing treatments like benzoyl peroxide, topical retinoids, and oral isotretinoin for severe cases, and issued conditional recommendations for therapies like salicylic acid and spironolactone, while offering good practice statements on combining treatment methods.

This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.

In this bibliometric analysis, researchers found an increasing focus on innovative treatments for androgenetic alopecia, such as platelet-rich plasma and stem cell therapy, with the United States and China leading in research contributions between 2003 and 2023.

This source summarizes the new 2024 American Academy of Dermatology guidelines, emphasizing strong recommendations for topical and oral therapies like benzoyl peroxide, doxycycline, and isotretinoin in managing acne vulgaris, while outlining the importance of tailored treatments for diverse patient needs in Canadian practice.

This review of acne management strategies highlights current treatments, such as topical and systemic therapies, procedural methods, and dietary changes, while also discussing emerging options like biologics and probiotics as potential future treatments, emphasizing personalized care due to acne's complex nature.

This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.

This study found that a single application of 0.1% aqueous benzalkonium chloride solution effectively treated dermatomycosis caused by Trichophyton species in guinea pigs.

In this case study, an 11-year-old girl with a Cladosporium scalp infection showed significant improvement in hair growth and appearance after treatment with itraconazole.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

This study concluded that the topical gel VB1953 reduced inflammatory and non-inflammatory acne lesions and resistant bacteria in patients with clindamycin-resistant acne, showing promise as an effective treatment.

Clofazimine may be effective for treating ashy dermatosis.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.